Can a nasal spray slow Alzheimer's? new trial aims to find out
NCT ID NCT07178678
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial will test whether a nasal spray called NeuroEPO can help maintain thinking and memory in people with mild to moderate Alzheimer's disease. About 90 adults aged 50 and older will receive either NeuroEPO or a placebo three times a week for one year. Researchers will measure changes in cognitive function and monitor for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NeuroEPO (a form of erythropoietin given as a nasal spray)
- What this could lead to
- If it works, this could point toward a new way to slow memory loss and thinking problems in people with early-to-moderate Alzheimer's disease.
- What could go wrong
- This is a small, early-phase trial (90 people) testing a drug that has not been proven effective for Alzheimer's. It may show no benefit or cause unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MILD ALZHEIMER'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Saskatchewan
Saskatoon, Saskatchewan, S7N5E5, Canada